It appears the ITP has cancelled it's plans to test glynac

#1

https://www.nia.nih.gov/research/dab/interventions-testing-program-itp/supported-interventions

It used to be listed as part of the 2024 cohort. You can see it was on the list in the past on the waybackmachine (so no “Mandela effect” here)

Also worth noting that “Trametinib + Rapamycin” was changed to Trametinib only.

Honestly REALLY disappointing if they chose to axe glynac as that looked to be the most promising one. Changing “Trametinib + Rapamycin” to just Trametinib on the other hand could be justified as wanting to see it if extends lifespan on it’s own before testing it with rapa.

10 Likes
#2

That’s so stupid.

#3

Maybe the words you’re looking for are “funding cuts”

3 Likes
#4

It is too bad that they would rather test things we have no access to as opposed to a highly promising supplement like GlyNac which we can order online and receive at our doorstep tomorrow

1 Like
#5

Yes. It appears that you are correct and GLYNAC has been removed from ITP testing. That’s a bummer. They are testing taurine though.

Compounds Currently being tested at the end of the list.

http://www.nia.nih.gov/research/dab/interventions-testing-program-itp/supported-interventions

5 Likes
#6

Has anyone spoken to Richard Miller recently? I wonder how the itp program has been impacted…

4 Likes
#7

GlyNAC extended mouse lifespan by 24% in this study. This should have been priority number one for the ITP

8 Likes